SLC18A1 and Huntington disease: By combining synergistic β<sub>1</sub>-adrenergic antagonism, VMAT2-mediated dopamine modulation, and VMAT1 inhibition, SOM3355 may address monoamine neurotransmitter imbalances within basal ganglia and cortical circuits involved in motor and neuropsychiatric manifestations of HD.